Literature DB >> 19258666

Role of endocannabinoids in cardiovascular shock.

B Malinowska1, S Lupinski, G Godlewski, U Baranowska, E Schlicker.   

Abstract

Endocannabinoids (e.g. anandamide, 2-arachidonoylglycerol or virodhamine) regulate the function of the cardiovascular system mainly in the following way: 1) by acting via CB(1) receptors, 2) by activation of CB(2) receptors, and 3) by modifying the function of vanilloid TRPV1, serotonin 5-HT(3) and alpha(7)-subunit-containing nicotinic acetylcholine receptors. Endocannabinoids are implicated in the pathogenesis of hypertension and of hypotension associated with haemorrhagic, endotoxic, and cardiogenic shock, and with advanced liver cirrhosis. There is also evidence for their involvement in the control of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19258666

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  4 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Do cannabinoids exhibit a tyramine-like effect?

Authors:  Eman Ilayan; Monika Feliszek; Barbara Malinowska; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-07-31       Impact factor: 3.000

Review 3.  Exploration of Multiverse Activities of Endocannabinoids in Biological Systems.

Authors:  Tapan Behl; Rashita Makkar; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

4.  A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats.

Authors:  Agnieszka Zakrzeska; Eberhard Schlicker; Marta Baranowska; Hanna Kozłowska; Grzegorz Kwolek; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2010-01-25       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.